Ledipasvir ( GS5885; GS-5885; GS 5885; Ledipasvir )

Catalog No. M17226 CAS No. 1256388-51-8

COA

Datasheet

HNMR

HPLC

MSDS

Handing Instructions

Group Booking Get Quotation Bulk Inquiry Add to Cart

Product Name

Ledipasvir
Note

Research use only, not for human use.
Brief Description

Ledipasvir is a Hepatitis C Virus NS5A Inhibitor. The mechanism of action of ledipasvir is as a P-Glycoprotein Inhibitor, and Breast Cancer Resistance Protein Inhibitor.
Description

Ledipasvir, also known as GS-5885; is an inhibitor of the hepatitis C virus NS5A protein and is a drug for the treatment of hepatitis C that was developed by Gilead Sciences. On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg (trade name Harvoni). The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.
Synonyms

GS5885; GS-5885; GS 5885; Ledipasvir
Pathway

Cell Cycle/DNA Damage
Target

HDAC
Recptor

GT1a; GT1b
Research Area

Infection
Indication

——

CAS Number

1256388-51-8
Formula Weight

889
Molecular Formula

C49H54F2N8O6
Purity

98%
Solubility

DMSO : 50 mg/mL. 56.24 mM;H2O : < 0.1 mg/mL
SMILES

O=C(OC)N[C@H](C(=O)N1[C@H](c2ncc(c3cc4C(F)(F)c5c(ccc(c6ccc7nc([C@H]8N(C(=O)[C@@H](NC(=O)OC)C(C)C)[C@@H]9CC[C@H]8C9)[nH]c7c6)c5)c4cc3)[nH]2)CC2(C1)CC2)C(C)C
Chemical Name

Methyl N-[(2S)-1-[(6S)-6-[5-[9,9-Difluoro-7-[2-[(1S,2S,4R)-3-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]-3-azabicyclo[2.2.1]heptan-2-yl]-3H-benzimidazol-5-yl]fluoren-2-yl]-1H-imidazol-2-yl]-5-azaspiro[2.4]heptan-5-yl]-3-methyl-1-oxobutan-2-yl]carbamate

1. Smith MA, et al. Ann Pharmacother. 2015 Mar;49(3):343-50.

Calculator

molnova catalog